Eos BioInnovation

Autoimmunity BioSolutions is a biotechnology company developing innovative solutions for autoimmune diseases, with a focus on multiple sclerosis. Their core technology involves a next-generation immuno-corrective therapy, tailored to a specific genetic subgroup of autoimmune patients. This therapy aims to restore normal immune function by targeting a specific genetic variant (SNP) driving the autoimmune pathology. The company's platform enables targeted modulation of the immune system, offering potential clients a means to correct immune system dysfunction with precision therapies.

HDAX Therapeutics is a biotechnology company focused on developing small molecule therapeutics for cardiovascular and neurological diseases, with an emphasis on HDAC6-driven pathologies such as neuropathies and cardiometabolic disorders. The company is building a precision therapeutics platform based on a two-site binding mechanism to selectively inhibit HDAC6, aiming to deliver safe, efficacious, and long-lasting treatments that enable researchers to pursue novel therapies with improved accuracy and therapeutic potential.